Hidradenitis Suppurativa Treatment Extension Study

A Novartis multicenter, double-blind, randomized withdrawal extension study of subcutaneous XXXXXXXXXX to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # CAIN457M2301E1

Share this post

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Call us, write us, or knock on our door.

Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.